Retinoblastoma is a type of cancer that affects the light sensitive lining at the back of the eye (called the retina). It is very rare, affecting around 40 children a year in the UK – about 3 per cent of all childhood cancer cases.

About retinoblastoma

Retinoblastoma is an embryonal tumour (arising in primitive developing cells) and, as such, most cases occur in very young children.

Retinoblastoma is one of only a very small number of childhood cancers that is caused by a genetic defect inherited from parents. Around 40 per cent of retinoblastoma cases are of the heritable form.

Retinoblastoma can be either unilateral (one eye, around two thirds of cases), or bilateral (both eyes). All children with bilateral tumours have the heritable disease, whereas only 10 per cent of unilateral cases have the heritable form.

The heritable form of retinoblastoma is now well understood. It occurs as a result of two alterations (called mutations) in the ‘retinoblastoma suppressor gene’ (RB1). The abnormal gene can be passed from a parent to their child, allowing the tumour to develop. Or this alteration can occur spontaneously while the baby is developing in the uterus.

Children with the heritable form have an increased risk of developing other types of cancer later in life.

Genetic counselling and support is available for families in which a member has retinoblastoma. Not all children of an affected parent will inherit the faulty gene but all children born into families with a history of retinoblastoma will be screened regularly during their first five years of life for signs of retinoblastoma so that treatment can be started early if a tumour does develop.

The causes of the non-heritable form of retinoblastoma are not understood.


Around 40 children are diagnosed with retinoblastoma every year in the UK. Almost all of those affected are under five years of age. More than 40 per cent of cases occur within the first year of life.

Most of the bilateral cases – which represent just over a third of cases overall – are diagnosed in the first year of life.

Overall, incidence is similar among males and females but there is a male excess of bilateral retinoblastoma (5:4) and a female excess of unilateral retinoblastoma (6:5).


Advances in the diagnosis and treatment of retinoblastoma mean that almost every child can be cured. Data for the period 2006 to 2010 show a five year survival rate of 100 per cent.

Unfortunately, however, survival may be at the expense of some or all of the child’s sight.


Many of the heritable cases of retinoblastoma will be picked up by screening before any symptoms have been detected.

Where there is no family history, the first sign of retinoblastoma is often a white pupil that does not reflect the light. This is called leucocoria and is sometimes detected in photographs taken using flash photography – the affected eye may look white in the photograph (loss of the red-eye effect). Some children may have a squint or - if the tumour is large - a painful, red eye. In older children, retinoblastoma can be picked up as a result of deteriorating vision.

Diagnosis will be confirmed by an examination under anaesthetic. Unlike most other types of cancer, retinoblastomas can be diagnosed just by their appearance – a biopsy is not usually necessary.

Once retinoblastoma is diagnosed, other tests may be carried out to check the exact position and size of the tumour, and whether it has spread. This is known as staging. These tests may include an ultrasound scan, an MRI scan and a lumbar puncture. A bone marrow sample may be taken to check whether there has been any spread of the cancer to the bone marrow and a blood sample may be taken for genetic testing.

Intraocular retinoblastoma has not begun to spread to other parts of the eye or into the tissues surrounding the eye. This group can be further divided into 5 further subgroups (A to E) depending on the size, position and amount of damage to the eye/s. This helps doctors decide which treatment is best.

Extraocular retinoblastoma has spread beyond the eye and into the tissue surrounding it or to other parts of the body.


Treatment depends on a number of factors including the staging (see above) of the tumour/s. The main aim of treatment is to eradicate the cancer. Unfortunately this means some patients may lose some or all of their sight as a result, although every effort is made to preserve sight.

Smaller tumours have local treatment just to the eye itself with laser therapy, freezing therapy (cryotherapy), or heat therapy (thermotherapy) to destroy the tumour. For slightly larger tumours, a small radioactive disc (known as a plaque) may be attached to the outside of the eye for up to four days to destroy the cancer cells.

Larger tumours may be treated with chemotherapy, radiotherapy or with surgery to remove the eye (called enucleation) if the sight is already lost. A combination of treatments may be necessary.

When the eye is removed, a prosthesis (false eye) will be fitted.

Read more: Commonly used terms in treatment

Side effects and complications of treatment

The risk of side effects will depend on the particular treatment being used. Sometimes these can occur years later, called late effects. The child’s doctor will discuss the risks before treatment starts.

Read more: Side effects of treatment


Children will have regular follow-ups to check for any recurrence of the cancer and for any problems which may arise as a result of the treatment they were given.

Following treatment, the child’s eye will be regularly examined by an eye specialist to check that the retina is healthy, the cancer has not come back, and no new tumours have developed.

A small number of children may develop long-term problems because of their cancer treatment.

Surgery and radiotherapy may both cause functional or cosmetic problems. Chemotherapy may cause problems with heart and kidney function, fertility problems and a small increase in risk of developing another cancer.

If the tumour comes back after the initial treatment it is called relapse. Nearly all the children with unilateral tumours survive without any recurrence. However with bilateral disease there is a greater chance it can recur. This recurrence may be in the eye, local tissue surrounding the eye, or in another part of the body.

Children with heritable retinoblastoma will be given genetic counselling when they are old enough to understand.

Children with heritable disease face an increased risk of develop other types of cancer in later life and so will be followed-up into adulthood. They will be encouraged to get any new symptoms checked early and to follow a health lifestyle to help reduce cancer risk.

Read more: Long-term and late effects of treatment


The child may be invited to participate in a clinical trial.

Trials aim to improve understanding of the best way to treat the cancer, usually by comparing the standard treatment with a new or modified version.

Children with Cancer UK is funding a number of research projects focused on retinoblastoma.

Read more: Current research projects

Further information

More detailed information about retinoblastoma and its treatment is available from Macmillan Cancer Support

Where your money goes

Hover over a segment for details